Inhibikase Therapeutics Stock (NASDAQ: IKT)

Dernières nouvelles pour Inhibikase Therapeutics (NASDAQ:IKT) Stock

Inhibikase Therapeutics

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics Inc

iTokk Inc

INTERTEK GROUP PLC ORD by Intertek Group Plc

Intertek Group PLC

INTERTEK GROUP UNSP/ADR by Intertek Group Plc

Rosenblatt analyst Mike Genovese maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Buy and maintains $20 price target.

News

Price Target

Analyst Ratings

AAOI

Rosenblatt Maintains Buy on Applied Optoelectronics, Maintains $20 Price Target

Macquarie analyst Tao Qiu maintains Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) with a Outperform and maintains $8 price target.

Macquarie Maintains Outperform on Brookdale Senior Living, Maintains $8 Price Target

DA Davidson analyst Linda Bolton Weiser initiates coverage on Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Neutral rating and announces Price Target of $159.

Initiation

DA Davidson Initiates Coverage On Procter & Gamble with Neutral Rating, Announces Price Target of $159

Actor Jim Belushi compared the similarities of acting and cannabis to an audience at the<a href="https://www.benzinga.com/events/cannabis-conference/"> Benzinga Cannabis Capital Conference on Oct. 9.</a>
Here's a look at what makes the two sectors similar and more on Belushi's journey to help people through cannabis.
Acting to Cannabis: Belushi may be best known for his roles in television and movies, but at the 2024 Benzinga Cannabis Capital Conference, the audience and other speakers are aware of his efforts in <a href="https://www.benzinga.com/markets/cannabis/24/09/40720303/hollywood-star-jim-belushi-brings-cannabis-expertise-to-chicago-conference-in-october">the cannabis sector.</a>
The actor said "It's been a great journey" going from one farm to now having products sold in 14 states.
Cannabis is like acting, Belushi told the crowd.
Belushi said as an actor he asked himself why he was doing acting and it came down to the idea of making people feel good.
"You want them to leave the theater feeling good," Belushi said.
Belushi said the switch to cannabis comes with the same mentality.
"Adding on cannabis to my purpose, the purpose is the same. Cannabis makes people feel good."
The actor and cannabis entrepreneur said cannabis can help with pain, increase happiness and make people feel better overall. "I feel like I am totally on purpose from actor to cannabis," he said.
Belushi, who stars in "Growing Belushi," which airs on Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)-owned Discovery, credits his partners and relationships in the industry for helping his growth.
"We are bred on a plant that is based on kindness, generosity and healing."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41233018/exclusive-ross-gerber-sees-tsunami-of-money-pouring-into-cannabis-companies-upon-federal-legaliz">EXCLUSIVE: Ross Gerber Sees &#8216;Tsunami Of Money&#8217; Pouring Into Cannabis Companies Upon Federal Legalization, Says Cannabis Is One Of &#8216;Biggest&#8217; Opportunities Beyond AI</a>
Challenges of Cannabis: Belushi said one of the main differences between cannabis and "show business" is the amount of time it takes to get things done.
Within the cannabis industry, the biggest challenge Belushi highlighted was the price. "Growing is very expensive," Belushi said.
The actor and entrepreneur said the market is oversaturated and it's hard to make any margin in states like Oregon.
Asked later on about his advice to someone looking to start their own grow farm, Belushi answered, "Don't do it. Don't f&#x2A;&#x2A;&#x2A;ing do it."
Belushi admitted he never got involved in cannabis for the money and was just hoping to break even, adding "I already got my TV money."
Belushi said he got involved in cannabis and remains involved despite the struggles as people should focus on things they're passionate about.
"I have passion for what this plant can bring to our community."
 What's Next: Belushi said he was excited about the potential for rescheduling happening this year and questions why it hasn't happened.
Until rescheduling happens, Belushi said doctors at Veteran Affairs can't give people cannabis instead of oxycontin.
"Why aren't we taking care of them?" Belushi asked of the country's veterans.
Belushi also said he was disappointed to see Vice President Kamala Harris talk about putting so many people in California into jail when many were put in there for marijuana-related crimes. The actor noted that he is not anti-Harris, but disagrees in this matter.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241368/exclusive-elon-musks-x-is-safe-space-to-say-weed-the-only-social-platform-where-you-can-talk-abo">EXCLUSIVE: Elon Musk&#8217;s X Is &#8216;Safe Space&#8217; To Say Weed: &#8216;The Only Social Platform Where You Can Talk About Cannabis Openly&#8217;</a></li>
</ul>
Photo: Jim Belushi at the Benzinga Cannabis Conference 2024, Photo by Wendy Davis

Cannabis

Entertainment

Events

Exclusives

Jim Belushi Compares Passion For Acting To Cannabis Business: 'Makes People Feel Good'

UBS analyst Trung Huynh maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and raises the price target from $50 to $54.

UBS Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $54

UBS analyst Colin Bristow maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $142 to $136.

UBS Maintains Buy on Merck & Co, Lowers Price Target to $136

UBS analyst Navin Jacob maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral and raises the price target from $185 to $195.

ABBV

UBS Maintains Neutral on AbbVie, Raises Price Target to $195

UBS analyst Jay Sole maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and raises the price target from $225 to $226.

DECK

UBS Maintains Buy on Deckers Outdoor, Raises Price Target to $226

UBS analyst Dennis Geiger maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Buy and raises the price target from $305 to $345.

UBS Maintains Buy on McDonald's, Raises Price Target to $345

Citigroup analyst Christopher Allen maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and raises the price target from $32 to $37.

VIRT

Citigroup Maintains Buy on Virtu Finl, Raises Price Target to $37

Citigroup analyst Thomas Palmer maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy and raises the price target from $79 to $80.

MDLZ

Citigroup Maintains Buy on Mondelez International, Raises Price Target to $80

Following the Arrangement, BIPC shareholders will own an economically equivalent security that provides the same economic benefits and governance of investing in our company today. The Arrangement is also expected to be tax-deferred for the vast majority of investors, including Canadian and U.S. shareholders.

BIPC

Brookfield Infrastructure Partners, Brookfield Infrastructure Reveal Intention To Complete Reorganization

As the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference </a>came to a close on Wednesday, attendees were treated to the announcement of the winners of the 2024 Benzinga Hemp Beverage Competition. This year's awards showcased the top D9 THC-infused beverages in various categories, celebrating innovation and craftsmanship in cannabis beverages. 
Here's a look at the standout products that took home the top honors.
<h3 class="wp-block-heading">Best D9 THC-Infused Tonic/Elixir</h3>
Winner: Drink Brez D9 THC-Infused Lemon Elderflower Tonic. 
Known for its harmonious blend of THC, CBD, and Lion&#8217;s Mane, Drink Brez promotes a more approachable experience for consumers. Described as delivering "brighter colors, louder laughs, and tastier snacks," the tonic is gaining popularity for being a no-hangover alternative to alcohol, combining organic ingredients with federally legal THC.
Runner-up: Forward Beverage Co. D9 THC-Infused In-Fashioned Social Seltzer. 
Forward Beverage Co. earned runner-up with its In-Fashioned Social Seltzer, which emphasizes providing alternatives to alcohol. This beverage, crafted to be savored socially, has been making waves in Wisconsin as a non-alcoholic option that doesn't leave anyone feeling left out.
<h3 class="wp-block-heading">Best D9 THC-Infused Soda</h3>
Winner: Mary Jones D9 THC-Infused Root Beer. 
Mary Jones continued its legacy of crafting sodas with an extra kick by taking the top spot in the D9 THC-infused soda category. With a reputation for delivering exceptional flavors since 1996, Mary Jones' Root Beer is infused with cannabis while maintaining the same "best damn cane sugar soda" standards the company is known for.
Runner-up: Mary Jones D9 THC-Infused Berry Lemonade Soda. 
Mary Jones&#8217;s Berry Lemonade Soda also earned accolades, securing runner-up in this category. Known for its bold flavors, this soda is another testament to the company's commitment to innovation and customer satisfaction.
Also Read: <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a>
<h3 class="wp-block-heading">Best D9 THC-Infused Seltzer</h3>
Winner: Share D9 THC-Infused Cucumber &amp; Lime Seltzer. 
Share took the top prize in the seltzer category with their refreshing Cucumber &amp; Lime Seltzer. This beverage is produced with an emphasis on excellence, from "seed to table," ensuring quality cannabis is used in every sip.
Runner-up: Wynk D9 THC-Infused Juicy Mango Seltzer. 
Wynk's Juicy Mango Seltzer claimed the runner-up position, winning over judges with its promise of consistency and balance. Wynk prides itself on delivering an exact dose with each can, allowing consumers to enjoy a reliably social experience.
<h3 class="wp-block-heading">Best D9 THC-Infused RTD (Ready to Drink)</h3>
Winner: Better Than Booze D9 THC-Infused Rosemary Grapefruit Paloma. 
Better Than Booze took the spotlight in the RTD category with their Rosemary Grapefruit Paloma. Co-founded by Drea Groeschel, this beverage provides a refreshing alternative to traditional alcoholic cocktails. Inspired by the desire to "swap out regular wine for a better alternative," the drink replicates classic cocktail flavors without the hangover.
Runner-up: Howdy D9 THC-Infused Paloma. 
Howdy's Texas-born D9 THC-infused Paloma earned the runner-up award with its Cosmic Cowboy branding and focus on low-dose, fast-acting beverages. Known for being &#8216;best-served cold and enjoyed socially,&#8217; Howdy is gaining a reputation for making cannabis-infused drinks that are both effective and enjoyable.
<h3 class="wp-block-heading">Best D9 THC-Infused Coffee/Tea</h3>
Winner: Howdy D9 THC-Infused Sweet Tea.
Howdy returned to the winner's circle, taking the top prize in the D9 THC-infused coffee/tea category with their Sweet Tea. A smooth blend of classic Southern flavors infused with THC, this drink is redefining what tea can be.
Runner-up: Squoze D9 THC-Infused Ahhhnold Kush Tea &amp; Lemonade.
Squoze secured the runner-up award with their Ahhhnold Kush Tea &amp; Lemonade. Known for being "squoze from fresh fruit," Squoze is making a name for itself by infusing traditional beverages with bold, cannabis-infused twists.
With the Benzinga Cannabis Capital Conference now concluded, these award-winning beverages continue to shine as leaders in the growing THC-infused beverage market. Look out for more insights and innovations from the cannabis industry's top players.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41259102/exclusive-cannabis-tech-leaders-push-personalization-data-insights-as-key-to-beating-price-wars">EXCLUSIVE: Cannabis Tech Leaders Push Personalization, Data Insights As Key To Beating Price Wars</a></li>
</ul>
Photo by Wendy Davis.

Benzinga Cannabis Capital Conference Celebrates Best D9 THC Beverages Of 2024

The&nbsp;$0.27&nbsp;per share quarterly cash dividend will be paid on&nbsp;January 8, 2025, to stockholders of record on&nbsp;December 13, 2024.&nbsp;

Dividends

AVNT

Avient Boosts Annual Dividend By 5% From $1.03 To $1.08 Per Share

Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) shares traded higher on heavy volume Wednesday after marking a new 52-week low on Tuesday. Here's a <a href="https://www.benzinga.com/news/24/10/41216891/celsius-holdings-stock-hit-52-week-lows-on-monday-whats-going-on">look at what's going on.&nbsp;</a>
What To Know: Celsius Holdings shares climbed Wednesday despite a lack of company-specific news. The stock has become a favorite among retail investors and chatter on social media revolved around the stock reaching key support levels and bouncing higher.&nbsp;
Celsius shares reached a 52-week high of $99.62 back in March and have fallen more than 60% over the past six months, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41234302/whats-going-on-with-sofi-stock">What&#8217;s Going On With SoFi Stock?</a>
The sell-off in Celsius shares accelerated in September after the company said PepsiCo was scaling back orders to <a href="https://www.benzinga.com/news/24/09/40733143/whats-going-on-with-celsius-holdings-stock">optimize its inventory</a>. Celsius said it expected its distribution partner to reduce orders by about $100 million.
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Celsius shares are trading above the stock&#8217;s 50-day moving average of $36.23 and slightly above its 52-week low of $28.20.&nbsp;
<h1 class="wp-block-heading">CELH Stock Prediction 2024</h1>
When buying a stock for a longer time horizon, it is important for investors to assess where they think the stock is headed in the future.
When mapping a stock's future trajectory, investors should consider factors including future earnings expectations and expected performance against a benchmark.
Celsius Holdings&#8217; revenue has grown at an average rate of 98.52% annually over the past five years. The average one-year price target from analysts is $53.64, representing an expected 75.81% upside in 2025.
While past performance is not a guarantee of future results, investors should also look at a stock's historical performance when compared to both a benchmark index and the company's peers. Shares of Celsius Holdings have seen an annualized return of -3.06%, underperforming the S&amp;P500 index by 12.72%. This compares to 7.79% growth in the overall Consumer Staples sector. Celsius Holdings has a beta of 0.92.
CELH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Celsius Holdings shares are up 3.57% after-hours at $31.60 after climbing 6.16% in regular trading Wednesday.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41217379/google-must-open-play-store-to-competitors-judge-orders">Google Must Open Play Store To Competitors, Judge Orders</a></li>
</ul>
Photo: Courtesy of Celsius Holdings, Inc.

After-Hours Center

Movers

CELH

What Happened With Celsius Holdings Stock Today?

Citigroup analyst Thomas Palmer maintains Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) with a Neutral and lowers the price target from $63 to $60.

Citigroup Maintains Neutral on Tyson Foods, Lowers Price Target to $60

&#8220;Discounts will hurt your margins, but loyalty points won't," said Lisa Williams, founder of The Toke Agency, at <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga&#8217;s Cannabis Capital Conference on Oct. 9. </a>
Williams was one of several experts discussing how cannabis retailers can use data to not only improve margins but also strengthen customer retention. 
The panel, titled &#8220;Maximizing Margins: Leveraging Data for Effective Cannabis Retail Pricing and E-commerce Strategies,&#8221; was moderated by Debra Borchardt, co-founder of Green Market Report.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41259102/exclusive-cannabis-tech-leaders-push-personalization-data-insights-as-key-to-beating-price-wars">EXCLUSIVE: Cannabis Tech Leaders Push Personalization, Data Insights As Key To Beating Price Wars</a>
Williams said that the real key to maintaining margins in cannabis retail isn't slashing prices — it's using data to build loyalty. By offering perks such as points or exclusive access to events, dispensaries can entice customers to come back. 
"How you build loyalty is you give them rewards for keeping them," Williams noted. 
Williams' point was simple: build a brand that encourages loyalty rather than price-driven shopping.
<h1 class="wp-block-heading">Turning Messy Data Into Actionable Insights</h1>
Kris Walker, co-founder of Hoodie Analytics, took the conversation deeper into how data can drive better decisions.
 "The trick is not just collecting data — it's making sure you have the processes in place to leverage it," Walker said. His company provides retailers with real-time data that pulls from multiple sources, including POS systems and wholesale platforms.
What Walker wanted to make clear was that data on its own doesn't solve problems. Retailers need to know how to use it. "We take messy data and turn it into something operators can use to grow their businesses," he added. 
Whether it's pricing strategies, product assortment, or even timing sales, the right data can guide retailers to make smarter choices, allowing them to adapt to fast-moving market trends.
<h1 class="wp-block-heading">Combining Data Sources For A Full Picture</h1>
Jackie Gonzalez-Becerra, vice president of revenue at Weedmaps, echoed the need for retailers to take data seriously — but stressed that internal data isn't enough.
"It's not enough to just look at your sales. You need to bring in external data — whether it's from Hoodie, Headset or BDS — to get a complete view of what's happening in the market," she said.
Gonzalez-Becerra explained how Weedmaps works with dispensaries to help them integrate 17 years of consumer shopping data into their operations.
This kind of deep data integration can reveal market trends that retailers wouldn't otherwise see. With the holiday season coming up, she pointed out how critical it is to start planning promotions early and anticipate consumer behavior changes.
<h1 class="wp-block-heading">Proactive Planning with Data: Fluent's Strategy</h1>
Robert Beasley, CEO of Fluent, brought in a real-world example of how data helped his company stay competitive in Florida. Back in 2022, Fluent forecasted a 20% price compression in the market, forcing them to plan ahead and cut costs. 
"We realized we needed to be 20% more efficient in two years if we wanted to maintain our margins," Beasley said.
Instead of waiting for market conditions to shift and reacting too late, Fluent took a proactive approach. They used data to optimize everything from cultivation to product pricing, staying ahead of the curve rather than playing catch-up. Beasley's message was clear: it's not enough to just respond to market changes — businesses need to see them coming.
<h1 class="wp-block-heading">Creating A Data-Driven Culture</h1>
One of the key takeaways from the panel was the need for a data-driven culture in cannabis businesses. Beasley shared that many cannabis companies still make decisions based on gut feelings or anecdotal evidence. 
"Humans are incapable of making anecdotal decisions on large data sets," he said, pointing out that without the right data and tools, businesses risk missing key trends.
Walker added to this by noting that companies need to ensure their teams are equipped with the right KPIs and data access. "If you don't give your team the tools and accountability they need, data can become overwhelming," Walker said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a></li>
</ul>
Photo: Benzinga Cannabis Capital Conference 2024, photo by Wendy Davis

Markets

EXCLUSIVE: Why Loyalty Programs, Not Discounts, Are The Future Of Cannabis Retail

Citigroup analyst Thomas Palmer maintains Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) with a Buy and lowers the price target from $41 to $39.

Citigroup Maintains Buy on Kraft Heinz, Lowers Price Target to $39

Citigroup analyst James Hardiman maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy and raises the price target from $25 to $28.

Citigroup Maintains Buy on Carnival, Raises Price Target to $28

Guidance

BSET

Bassett Says Made Progress On Restructuring Plan Announced In July, On Target To Improve Bottom-line Between $5.5M And $6.5M On Annual Basis

Inhibikase Therapeutics prices its direct offering, warrant inducement

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evolus (EOLS – Research Report), Korro Bio (KRRO – R...

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inhibikase Therapeutics (IKT – Research Report), retaining the price target of $8....

Inhibikase Therapeutics: A Buy Rating on the Horizon with Promising Drug Developments

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zentalis Pharmaceuticals (ZNTL – Research Report), I...

Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (ZNTL), Inhibikase Therapeutics (IKT) and Intra-Cellular Therapies (ITCI)

Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibikase Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ikt-stock-quote/">IKT</a>) just reported results for the second quarter of 2024.<ul><li>Inhibikase Therapeutics reported earnings per share of -66 cents. This was above the analyst estimate for EPS of -67 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ikt-stock-earnings-inhibikase-therapeutics-for-q2-of-2024/">IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024

Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on their website detaili...

Inhibikase Therapeutics Unveils PAH and Parkinson's Drug Pipeline

Inhibikase Therapeutics stock rises after pricing $110M private offering

EOLS

ITCI

KRRO

ZNTL

Health Care

Press Releases

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Earnings

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

General

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

ABVC BioPharma

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Avalo Therapeutics

BioCardia

BioVie

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Carmell

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Forte Biosciences

Galecto

GlycoMimetics

Kintara Therapeutics, Inc. - Common Stock

Kintara Therapeutics

Mustang Bio

Moleculin Biotech

Molecular Templates

Mainz Biomed

Organovo Holdings

Portage Biotech

Plus Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Soligenix

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics

Xenetic Biosciences

HC Wainwright & Co.

WIIM

Inhibikase Therapeutics shares are trading higher after the com[any announced the pricing of an approximately $110 million private placement financing.

Comments

Inhibikase Therapeutics

Actualités

Dernières nouvelles pour Inhibikase Therapeutics (NASDAQ:IKT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL